Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification
Open Access
- 2 June 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 24 (10) , 3157-3162
Abstract
Background. Cardiovascular disease is the leading cause of death in the chronic kidney disease (CKD) population. The mechanisms of vascular damage are not fully understood. The objective of this study was to prospectively investigate the importance of novel mediators of vascular damage, in conjunction with vascular calcification (VC), on survival. Methods. A total of 134 subjects [60 haemodialysis (HD), 28 peritoneal dialysis (PD) and 46 CKD stage 4] were studied. All survivors completed 40 months of follow-up. VC was measured using multi-slice spiral CT of the superficial femoral artery. Circulating osteoprotegerin (OPG), Fetuin-A and high sensitivity C-reactive protein (hs-CRP) were measured in addition to standard clinical biochemical analysis. Results. After a 40-month follow-up, 31 patients had died (27 men and 4 women). Of 31 subjects, 31 had evidence of significant VC. The majority of deaths were in the HD group (48%), 36% were PD subjects and 16% were CKD subjects. The outcome of interest was survival at the end of follow-up. Multivariate logistical regression analysis revealed male gender [OR 8.06 (1.34–48.450) P = 0.02], OPG >25 pmol/L [OR 5.31(1.35–20.88) P = 0.02] and hypoalbuminaemia [OR 0.26 (0.12–0.56) P < 0.01], were associated with increased odds of death. Conclusion. We have previously reported that VC and low albumin predict death in CKD stages 4 and 5 over a 2-year follow-up period. These data show that OPG, independent of CRP, is also associated with a negative outcome. The mechanisms remain to be elucidated; however, it is likely that they are associated with vascular damage through mechanisms in addition to VC.Keywords
This publication has 26 references indexed in Scilit:
- The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysisNephrology Dialysis Transplantation, 2008
- Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2007
- Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 DiabetesDiabetes Care, 2006
- The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic SubjectsJACC, 2006
- Enhanced T-Cell Expression of RANK Ligand in Acute Coronary SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patientsNephrology Dialysis Transplantation, 2004
- Osteoclast differentiation and activationNature, 2003
- Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patientsKidney International, 2003
- Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery DiseaseCirculation, 2002
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997